These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 29299975)

  • 1. Castration is a prerequisite for the inhibitory effect of metronomic chemotherapy on the growth of experimental castration-resistant prostate cancer.
    Jellvert Å; Åhs D; Olausson J; Franck Lissbrant I; Damber JE; Welén K
    Acta Oncol; 2018 Jul; 57(7):895-901. PubMed ID: 29299975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced anti-tumor and anti-angiogenic effects of metronomic cyclophosphamide combined with Endostar in a xenograft model of human lung cancer.
    Wang R; Qin S; Chen Y; Li Y; Chen C; Wang Z; Zheng R; Wu Q
    Oncol Rep; 2012 Aug; 28(2):439-45. PubMed ID: 22641525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
    Thamilselvan V; Menon M; Thamilselvan S
    Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
    Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
    J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
    Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
    Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional and pharmacodynamic evaluation of metronomic cyclophosphamide and docetaxel regimen in castration-resistant prostate cancer.
    Cardillo I; Spugnini EP; Galluzzo P; Contestabile M; Dell'Anna ML; Picardo M; Crispi S; Calogero RA; Piccolo MT; Arigoni M; Cantarella D; Boccellino M; Quagliuolo L; Ferretti G; Carlini P; Felici A; Boccardo F; Cognetti F; Baldi A
    Future Oncol; 2013 Sep; 9(9):1375-88. PubMed ID: 23980684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor (AR) degradation enhancer ASC-J9
    Cheng MA; Chou FJ; Wang K; Yang R; Ding J; Zhang Q; Li G; Yeh S; Xu D; Chang C
    Cancer Lett; 2018 Mar; 417():182-191. PubMed ID: 29203251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
    Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
    Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model.
    Cheng L; Zhang S; Sweeney CJ; Kao C; Gardner TA; Eble JN
    Anticancer Res; 2004; 24(4):2135-40. PubMed ID: 15330153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical profile and phase I clinical trial of a novel androgen receptor antagonist GT0918 in castration-resistant prostate cancer.
    Zhou T; Xu W; Zhang W; Sun Y; Yan H; Gao X; Wang F; Zhou Q; Hou J; Ren S; Yang Q; Yang B; Xu C; Zhou Q; Wang M; Chen C; Sun Y
    Eur J Cancer; 2020 Jul; 134():29-40. PubMed ID: 32460179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
    Ishikura N; Kawata H; Nishimoto A; Nakamura R; Tsunenari T; Watanabe M; Tachibana K; Shiraishi T; Yoshino H; Honma A; Emura T; Ohta M; Nakagawa T; Houjo T; Corey E; Vessella RL; Aoki Y; Sato H
    Int J Oncol; 2015 Apr; 46(4):1560-72. PubMed ID: 25634071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resveratrol inhibits hypoxia-inducible factor-1α-mediated androgen receptor signaling and represses tumor progression in castration-resistant prostate cancer.
    Mitani T; Harada N; Tanimori S; Nakano Y; Inui H; Yamaji R
    J Nutr Sci Vitaminol (Tokyo); 2014; 60(4):276-82. PubMed ID: 25297617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the RANK/RANKL signaling with osteoprotegerin prevents castration-induced acceleration of bone metastasis in castration-insensitive prostate cancer.
    Takayama K; Inoue T; Narita S; Maita S; Huang M; Numakura K; Tsuruta H; Saito M; Maeno A; Satoh S; Tsuchiya N; Habuchi T
    Cancer Lett; 2017 Jul; 397():103-110. PubMed ID: 28373003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prostatic environment suppresses growth of androgen-independent prostate cancer xenografts: an effect influenced by testosterone.
    Jennbacken K; Gustavsson H; Tesan T; Horn M; Vallbo C; Welén K; Damber JE
    Prostate; 2009 Aug; 69(11):1164-75. PubMed ID: 19399749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor effects of carnertinib in castration resistant prostate cancer models: a comparative study with erlotinib.
    Gravina GL; Marampon F; Piccolella M; Biordi L; Ficorella C; Motta M; Jannini EA; Tombolini V; Festuccia C
    Prostate; 2011 Oct; 71(14):1481-91. PubMed ID: 21446006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
    Kerbel RS; Shaked Y
    Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.
    Derosa L; Galli L; Orlandi P; Fioravanti A; Di Desidero T; Fontana A; Antonuzzo A; Biasco E; Farnesi A; Marconcini R; Francia G; Danesi R; Falcone A; Bocci G
    Cancer; 2014 Dec; 120(24):3923-31. PubMed ID: 25111199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral simvastatin administration delays castration-resistant progression and reduces intratumoral steroidogenesis of LNCaP prostate cancer xenografts.
    Gordon JA; Midha A; Szeitz A; Ghaffari M; Adomat HH; Guo Y; Klassen TL; Guns ES; Wasan KM; Cox ME
    Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):21-7. PubMed ID: 26238234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
    Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
    Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth.
    Srivastava K; Hu J; Korn C; Savant S; Teichert M; Kapel SS; Jugold M; Besemfelder E; Thomas M; Pasparakis M; Augustin HG
    Cancer Cell; 2014 Dec; 26(6):880-895. PubMed ID: 25490450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.